GlaxoSmithKline plc (GSK) Receives $42.50 Consensus Price Target from Analysts

Share on StockTwits

Shares of GlaxoSmithKline plc (NYSE:GSK) have earned a consensus rating of “Hold” from the twenty-one analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $42.50.

Several research firms recently issued reports on GSK. UBS Group cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Shore Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, Zacks Investment Research upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Monday, February 4th.

Shares of GSK stock traded up $0.19 during trading hours on Monday, hitting $40.18. 1,701,862 shares of the company’s stock were exchanged, compared to its average volume of 2,465,125. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72. The stock has a market capitalization of $99.67 billion, a PE ratio of 12.72, a PEG ratio of 2.07 and a beta of 0.74. GlaxoSmithKline has a 52 week low of $36.41 and a 52 week high of $42.36.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.66 by $0.13. The company had revenue of $9.98 billion for the quarter, compared to analysts’ expectations of $9.86 billion. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%. As a group, analysts forecast that GlaxoSmithKline will post 2.92 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.4953 dividend. This represents a $1.98 annualized dividend and a yield of 4.93%. The ex-dividend date of this dividend is Thursday, May 16th. GlaxoSmithKline’s payout ratio is 61.71%.

In related news, Director Plc Glaxosmithkline bought 325,000 shares of the business’s stock in a transaction on Monday, April 22nd. The shares were purchased at an average price of $18.00 per share, with a total value of $5,850,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Princeton Global Asset Management LLC acquired a new stake in shares of GlaxoSmithKline during the first quarter worth about $37,000. Rehmann Capital Advisory Group raised its position in shares of GlaxoSmithKline by 46.5% during the first quarter. Rehmann Capital Advisory Group now owns 4,066 shares of the pharmaceutical company’s stock worth $170,000 after purchasing an additional 1,290 shares during the period. GYL Financial Synergies LLC acquired a new stake in shares of GlaxoSmithKline during the first quarter worth about $1,826,000. Columbia Asset Management raised its position in shares of GlaxoSmithKline by 11.9% during the first quarter. Columbia Asset Management now owns 20,548 shares of the pharmaceutical company’s stock worth $1,300,000 after purchasing an additional 2,185 shares during the period. Finally, M Holdings Securities Inc. raised its position in shares of GlaxoSmithKline by 26.1% during the first quarter. M Holdings Securities Inc. now owns 9,557 shares of the pharmaceutical company’s stock worth $399,000 after purchasing an additional 1,978 shares during the period. 11.28% of the stock is currently owned by hedge funds and other institutional investors.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Percentage Decliners

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report